Beaumont Hospital - Royal Oak is the first in Michigan and one of just a handful in the United States to offer fractional flow reserve by computed tomography, also known as FFR-CT. The technology is a noninvasive, diagnostic tool recently approved by the U.S. Food and Drug Administration (FDA) and developed by HeartFlow Inc.

Procyrion Inc. of Houston has been awarded the grand prize of $20,000 in the 2015 "Create the Future" Design Contest for the first catheter-deployed heart pump intended for long-term treatment of chronic heart failure.

October 5, 2015 — The U.S. Food and Drug Administration (FDA) has approved Boston Scientific’s Synergy Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease. This is the first stent approved on the U.S. market that uses a metallic stent with a bioresorbable polymer drug-carrier rather than permanent polymers, which have been implicated as a cause of late-stent thrombosis. 

Healthcare Information and Management Systems Society (HIMSS)

With exceptional education, world-class speakers, cutting-edge technology and products, and powerful networking, the HIMSS Annual Conference & Exhibition is the health IT conference. We're pleased to announce that registration for HIMSS16 is now open.

Society for Cardiovascular Magnetic Resonance Annual Scientific Sessions

The 2016 SCMR Annual Meeting which will be held at the Hyatt Regency Century Plaza in Los Angeles, California. The event draws over 1,000 attendees.

SNMMI Mid-Winter and ACNM Annual Meeting

Leading molecular imaging and nuclear medicine physicians, radiologists, cardiologists, pharmacists, scientists, lab professionals, and technologists, representing the world's top medical and academic institutions and centers will be attending. 

Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the study presented by a prominent heart failure (HF) specialist during a major cardiology congress in the United States show that autonomic regulation therapy (ART) in patients with moderate to severe chronic HF and impaired heart function is well-tolerated, safe, improves the heart's ability to pump blood, and reduces the frequency and severity of symptoms associated with chronic HF.

October 2, 2015 — Tryton Medical Inc. announced that results of a post hoc analysis of the pivotal Tryton Randomized Clinical Trial (RCT) have been published in the peer-reviewed journal Catheterization and Cardiovascular Interventions (CCI). CCI is the official publication of the Society for Cardiovascular Angiography and Interventions (SCAI).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now